Jorge Cortes, MD
Independent Protocol Advisor · M.D. Anderson Cancer Center · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jorge Cortes, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:47 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03038230 · MCLA-117 in Acute Myelogenous LeukemiaMerus B.V. · terminated · Acute Myelogenous Leukemia, Acute Myeloid Leukemia · principal investigator
- Ph2NCT02730884 · Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaM.D. Anderson Cancer Center · terminated · Leukemia, Myelofibrosis, Anemia · principal investigator
- Ph1/Ph2NCT02400281 · Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia PatientsArog Pharmaceuticals, Inc. · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT02351037 · Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaPharmacyclics LLC. · terminated · Acute Myeloid Leukemia (AML) · principal investigator
- Ph2NCT01657682 · A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating MutationsArog Pharmaceuticals, Inc. · completed · Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies · principal investigator
- Ph1/Ph2NCT01606579 · Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid MalignanciesPrism Pharma Co., Ltd. · completed · Acute Myeloid Leukemia, Chronic Myeloid Leukemia · principal investigator
- Ph2NCT01570868 · Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1/Ph2NCT01498445 · An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1NCT01460498 · Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT01202877 · PKC412 and 5-AzacytidineM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT01167166 · Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)Traws Pharma, Inc. · completed · Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease · principal investigator
- Ph1NCT01159028 · Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSBio-Path Holdings, Inc. · completed · Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome · study chair
- Ph1/Ph2NCT01101412 · Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesM.D. Anderson Cancer Center · withdrawn · Chronic Myeloproliferative Disorders, Infection, Leukemia · study chair
- N/ANCT01099202 · Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation ChemotherapyM.D. Anderson Cancer Center · completed · Leukemia · study chair
- Ph2NCT01031498 · Palonosetron Versus Ondansetron for the Prevention of Nausea and VomitingM.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting · study chair
- Ph2NCT00956787 · Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)Arno Therapeutics · unknown · Myelodysplastic Syndrome · principal investigator
- Ph2NCT00954941 · Ondansetron Versus Aprepitant Plus Ondansetron for EmesisM.D. Anderson Cancer Center · completed · Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome · study chair
- Ph2NCT00936117 · Pharmacokinetics of Posaconazole Prophylaxis in Acute LeukemiaM.D. Anderson Cancer Center · completed · Leukemia, Fungal Infection · study chair
- Ph3NCT00904995 · Beta Glucan Assay in Patients Receiving Voriconazole ProphylaxisM.D. Anderson Cancer Center · completed · Leukemia, Fungal Infection · study chair
- Ph1NCT00827138 · Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)Deciphera Pharmaceuticals, LLC · completed · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT00520208 · Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APLCytRx · completed · Acute Promyelocytic Leukemia · principal investigator
- Ph2NCT00462943 · Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CMLTeva Branded Pharmaceutical Products R&D, Inc. · completed · Chronic Myeloid Leukemia · principal investigator
- N/ANCT00378781 · Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related InfectionM.D. Anderson Cancer Center · withdrawn · Cancer · principal investigator
- Ph2NCT00375219 · Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene MutationTeva Branded Pharmaceutical Products R&D, Inc. · completed · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT00129740 · Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)M.D. Anderson Cancer Center · completed · Leukemia, Myelogenous, Chronic · principal investigator
- Ph1NCT00004263 · Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Leukemia, Myelodysplastic Syndromes · study chair
- Ph1NCT00003693 · Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center · completed · Leukemia, Myelodysplastic Syndromes · study chair
- Ph1/Ph2NCT00030355 · Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic LeukemiaNational Cancer Institute (NCI) · withdrawn · Leukemia · study chair
- Ph2NCT00023881 · Bortezomib in Treating Patients With Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center · terminated · Leukemia · study chair
- N/ANCT00038675 · Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateM.D. Anderson Cancer Center · completed · Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera · principal investigator
- Ph2NCT00038597 · Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)M.D. Anderson Cancer Center · completed · Myelogenous Leukemia, Chronic · principal investigator
- Ph1NCT00038051 · Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid MalignanciesM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloproliferative Disorders · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
- Phase I Studies of Targeted Anti-Cancer TherapiesU01CA062461 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI James C Yao · fiscal years 2013Named on NCT00004263, NCT00003693
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.